IFN-β is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro

Cancer Research

Volumn 66, Issue 1, 2006, Pages 554-562

  Vitale, Giovanni ^a   De Herder, Wouter W ^a   Van Koetsveld, Peter M ^a   Waaijers, Marlijn ^a   Schoordijk, Wenda ^a   Croze, Ed ^b   Colao, Annamaria ^c   Lamberts, Steven W J ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BAYER AG   (Germany)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; BETA1A INTERFERON; CHROMOGRANIN A; DNA FRAGMENT; INTERFERON RECEPTOR; LIPOCORTIN 5; MESSENGER RNA; RECOMBINANT ALPHA2B INTERFERON;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOID; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; CARCINOID TUMOR; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHROMOGRANIN A; CHROMOGRANINS; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERFERON ALFA-2A; INTERFERON-BETA; MEMBRANE PROTEINS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; RNA, MESSENGER;

EID: 31544475735     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3043     Document Type: Article

References (50)

1. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumors. Endocr Relat Cancer 2004;11:1-18.
2. Caplin ME, Buscombe JR, Hilson AJ, Jones AC, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998;352:799-805.
3. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51.
4. Akerstrom G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol 2005; 89:161-9.
5. Lips CJM, Lentjes EGWM, Hoppener JWM. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem 2003;40:612-27.
6. de Herder WW, Krenning EP, van Eijck CHJ, Lamberts SWJ. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)-endocrine tumours of the gastrointestinal tract and pancreas. Endocr Relat Cancer 2004;11:19-34.
7. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187:88-92.
8. O'Toole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004;80:79-84.
9. 90Y-DOTA]-D-Phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-5.
10. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22.
11. 177Lu-DOTA0,Tyr3]-octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62.
12. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
13. de Herder WW, Lamberts SWJ. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002;14:53-7.
14. Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol 1991;30: 519-22.
15. Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32:203-8.
16. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123-31.
17. Horikoshi T, Fukuzawa K, Hanada N, et al. In vitro comparative study of the antitumor effects of human interferon-α, β and λ on the growth and invasive potential of human melanoma cells. J Dermatol 1995;22: 631-6.
18. Giandomenico V, Vaccari G, Fiorucci G, et al. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-α, interferon-β and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw 1998;9:619-31.
19. Rosenblum MG, Yung WKA, Kelleher PJ, Ruzicka F, Steck PA, Borden EC. Growth inhibitory effects of interferon-β but not interferon-α on human glioma cells: correlation of receptor binding 2′,5′- oligoadenylate synthetase and protein kinase activity. J Interferon Res 1990;10:141-51.
20. Coradini D, Biffl A, Pirronello E, Di Fronzo G. The effect of α-, β- and λ-interferon on the growth of breast cancer cell lines. Anticancer Res 1994;14:1779-84.
21. Damdinsuren B, Nagano H, Sakon M, et al. Interferon-β is more potent than interferon-α in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 2003;10:1184-90.
22. Hofland LJ, van Koetsveld PM, Lamberts SW. Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. Eur J Cancer 1990; 26:37-44.
23. Ochiai N, Uchida R, Fuchida SI, et al. Effect of farnesyl transferase inhibitos R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 2003;102: 3349-53.
24. Ferone D, Pivonello R, van Hagen PM, et al. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 2002;283:E1056-66.
25. Degorce F, Goumon Y, Jacquemart L, et al. A new human chromogranin-A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 1999;79:65-71.
26. De Maeyer E, De Maeyer-Guignard J. Type I interferons. Int Rev Immunol 1998;17:53-73.
27. Tagliaferri P, Caraglia M, Budillon A, et al. New pharmacokinetic and pharmacodynamic tools for interferon-α (IFN-α) treatment of human cancer. Cancer Immunol Immunother 2005;54:1-10.
28. Takaoka A, Taniguchi T. New aspects of IFN-α/β signalling in immunity, oncogenesis and bone metabolism. Cancer Sci 2003;94:405-11.
29. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000;85:983-8.
30. Deonarain R, Chan DCM, Platanias LC, Fish EN. Interferon-α/β- receptor interactions: a complex story unfolding. Curr Pharm Des 2002;8:2131-7.
31. Pestka S. The interferon receptors. Semin Oncol 1997; 24:S9-18-9-40.
32. Domanski P, Witte M, Kellum M, et al. Cloning and expression of a long form of the β subunit of the interferon αβ receptor that is required for signaling. J Biol Chem 1995;270:21606-11.
33. Cohen B, Novick D, Barak S, Rubinstein M. Ligand-induced association of the type I interferon receptor components. Mol Cell Biol 1995;15:4208-14.
34. Croze E, Russell-Harde D, Wagner TC, Pu H, Pfeffer LM, Perez HD. The human type I interferon receptor. Identification of the interferon β-specific receptor-associated phosphoprotein. J Biol Chem 1996;271: 33165-8.
35. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 2001;97:473-82.
36. McKenna SD, Vergilis K, Arulanandam AR, Weiser WY, Nabioullin R, Tepper MA. Formation of human IFN-β complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice. J Interferon Cytokine Res 2004;24:119-29.
37. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J Natl Cancer Inst 1992; 84:1185-90.
38. Zhou Y, Wang S, Gobi A, Oberg K. Inhibition of CDK2, CDK4 and cyclin E and increased expression of p27kip1 during treatment with interferon-α in carcinoid tumor cells. J Biol Regul Homeost Agents 1999;13:207-15.
39. Detjen KM, Welzel M, Farwig K, et al. Molecular mechanism of interferon α-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 2000;118:735-48.
40. Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. The three-dimensional high resolution structure of human interferon α-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol 1997;274:661-75.
41. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. The crystal structure of human interferon β at 2.2-A resolution. Proc Natl Acad Sci U S A 1997;94: 11813-8.
42. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 1999;27:1583-92.
43. Caraglia M, Tagliaferri P, Marra M, et al. EGF activates an inducible survival response via the RAS→Erk-1/2 pathway to counteract interferon-α mediated apoptosis in epidermoid cancer cells. Cell Death Differ 2003;10:218-29.
44. 1 phase cell cycle progression and S phase arrest. J Biol Chem 2005;280: 32107-14.
45. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998;78:1102-7.
46. Kolby L, Bernhardt P, Sward C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 2004;120:269-73.
47. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers. J Interferon Cytokine Res 2000;20:857-66.
48. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetica and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cytokine Res 1996;16:759-64.
49. Pepinsky RB, LePage DJ, Gill A, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001;297:1059-66.
50. Yoshida J, Mizuno M, Wakabayashi T. Interferon-β gene therapy for cancer: basic research to clinical application. Cancer Sci 2004;95:858-65.